Item 4. Controls and Procedures
ITEM
4. CONTROLS AND PROCEDURES
Evaluation
of Disclosure Controls and Procedures
As
of June 30, 2025, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive
and financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation,
management concluded that our disclosure controls and procedures were not effective as of June 30, 2025, to provide reasonable assurance
that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed,
summarized, and reported within the periods prescribed by U.S. Securities and Exchange Commission and that such information is accumulated
and communicated to management, including our chief executive and financial officer, as appropriate, to allow timely decisions regarding
required disclosure.
In
designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a
control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to
their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that
all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments
in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. The design of any system of controls
is based, in part, upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future conditions.
Changes
in Internal Control over Financial Reporting
There
has been no change in our internal control over financial reporting during the quarter ended June 30, 2025, that has materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.
20
PART
II—OTHER INFORMATION
ITEM
6. EXHIBITS
The
following exhibits are filed as a part of this report:
Exhibit
Number*
Title
of Document
Location
Item 31
Rule 13a-14(a)/15d-14(a) Certifications
31.01
Certification of Principal Executive and Principal Financial Officer Pursuant to Rule 13a-14
This filing.
Item 32
Section 1350 Certifications
32.01
Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
This filing.
Item 101
Interactive Data File
101.INS
Inline XBRL Instance Document
This filing.
101.SCH
Inline XBRL Taxonomy Extension Schema
This filing.
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase
This filing.
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase
This filing.
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase
This filing.
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase
This filing.
104
Cover Page Interactive Data File (embedded within the
Inline XBRL document)
*
All exhibits are numbered
with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal
indicating the document’s sequence.
**
The XBRL related information
in Exhibit 101 will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to liability of that section and will not be incorporated by reference into any filing or other document pursuant
to the Securities Act of 1933, as amended, except as is expressly set forth by specific reference in such filing or document.
21
SIGNATURE
PAGE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
CIRTRAN CORPORATION
Dated: August 19, 2025
By:
/s/
Iehab Hawatmeh
Iehab Hawatmeh, President
Principal Executive and Financial Officer
22
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.